Viveve Medical (NSDQ:VIVE) announced that the U.S. Patent & Trademark Office issued a patent for its stress urinary incontinence technology. USPTO issued U.S. Patent No. 10,779,874, allowing Viveve to expand its intellectual property portfolio ahead of its U.S. pivotal Pursuit clinical trial evaluating its treatment of SUI in women, according to a news release. Englewood, Colo.-based […]
Viveve Medical
Viveve Medical raises $3.2m
Viveve Medical (NSDQ:VIVE) filed an SEC Form D yesterday to confirm the sale of more than $3.2 million in options, warrants and other rights to acquire other securities. The company made the first sale in the offering on April 20 and has now sold the total offering amount of $3,225,875. There is a sales commission worth […]
Cutera, Senseonics and more receive Paycheck Protection Program loans
A number of medtech companies announced that they received millions of dollars in loans through the Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security (CARES) Act. Cutera (NSDQ:CUTR), Senseonics (NYSE:SENS), Viveve Medical (NSDQ:VIVE) and Encision (ECIA:ECIA) received approximately $15 million combined through the program administered by the U.S. Small Business Administration amid the COVID-19 pandemic. […]
Viveve looking at ‘stategic alternatives’ after trial misses the mark
Viveve Medical (NSDQ:VIVE) announced today that the clinical trial for its cryogen-cooled monopolar radiofrequency (CMRF) technology did not meet its primary endpoint. The company added that it is currently evaluating strategic alternatives and assessing its organization and cost structure following the missed endpoint amid the current COVID-19 pandemic. The Viveve II clinical trial is a multicenter, […]
Viveve Medical completes enrollment for study of its stress urinary incontinence treatment
Viveve Medical (NSDQ:VIVE) announced that it completed enrollment in a short-term feasibility study for its cryogen-cooled monopolar radiofrequency (CMRF) treatment for stress urinary incontinence (SUI) in women. The international, three-arm study is a prospective, randomized, single-blind clinical trial comparing Viveve’s CMRF treatment and a cryogen-only sham to an inert sham treatment in women with SU. Englewood, […]
Viveve Medical prices $10m offering
Viveve Medical (NSDQ:VIVE) entered into an underwriting agreement with Ladenburg Thalmann & Co. to price an offering of approximately $10 million. Last month, the company issued and sold 978,202 Class A units of common stock at a public offering price of $1.55 per unit, according to an SEC Form 8-K filing. It also issued nearly […]
Aegea Medical picks up former Cardiokinetix, Concentric Medical CEO Sainz | Personnel Moves – May 14, 2018
Aegea Medical said last week it tapped former Cardiokinetix prez & CEO Maria Sainz as its new president and chief executive officer, effective immediately. Sainz will replace former CEO Don Gurskis, who has held the corner office since 2013. Gurskis will remain on as member of the Redwood City, Calif.-based company’s executive management team. “Maria is […]
Viveve prices upcoming $30m offering
Viveve (NSDQ:VIVE) today priced an upcoming offering, looking to raise approximately $30 million to support continued clinical research and development and commercialization of its products. The Englewood, Colo.-based company said it will look to offer a total of 10 million shares in the round at $3 per share in the offering. The offering also includes a 30-day […]
Viveve wins Mexican clearance for Viveve system
Viveve (NSDQ:VIVE) said today it won approval from Mexico’s regulatory authority, COFEPRIS, to market its Viveve system in Mexico with indications for treating vaginal introitus, after vaginal childbirth and to improve sexual function. The Englewood, Colo.-based company’s Viveve System is designed as a non-surgical treatment for post-partum laxity of the vaginal introitus. The new regulatory clearance brings the […]
7 medtech stories we missed this week: Oct. 13, 2017
From Orthocell’s distribution deal to CorNeat unveiling its artificial cornea, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. OrthoCell inks Australian distro deal Orthocell announced in an Oct. 10 press release that it has signed a distribution deal with Surgical Specialities. The deal will make Surgical Specialities the […]
Viveve inks distro deal with InControl Medical, posts Q2 miss
Shares in Viveve (NSDQ:VIVE) have stayed steady today after the company announced a new exclusive distribution deal with InControl Medical and released 2nd quarter earnings that missed expectations on Wall Street. Under the agreement, Englewood, Colo.-based Viveve said it will be granted exclusive rights to distribute all of InControl Medical’s products to healthcare providers in the […]